Active Ingredient History

NOW
  • Now
Tenapanor is an inhibitor of the sodium-proton (Na(+)/H(+)) exchanger NHE3 and reduces sodium absorption in the GI tract, thus increasing intestinal fluid. Ardelyx has completed Phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation (IBS-C) and submitted a new drug application to the U.S. Food and Drug Administration for the treatment of patients with IBS-C. In addition, tenapanor successfully completed phase III clinical trial for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and RDX013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease.   NCATS

  • SMILES: CN1C[C@@H](c2cccc(c2)S(=O)(=O)NCCOCCOCCNC(=O)NCCCCNC(=O)NCCOCCOCCNS(=O)(=O)c3cccc(c3)[C@@H]4CN(C)Cc5c(Cl)cc(Cl)cc45)c6cc(Cl)cc(Cl)c6C1
  • InChIKey: DNHPDWGIXIMXSA-CXNSMIOJSA-N
  • Mol. Mass: 1145.07
  • ALogP: Missing data
  • ChEMBL Molecules:
More Chemistry
azd1722 | azd-1722 | azd-1722 hydrochloride | rdx5791 | rdx-5791 | tenapanor | tenapanor hydrochloride

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue